Oscient Pharmaceuticals’ (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, and lead product candidate, Ramoplanin, are the subject of several poster presentations at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Taking place in Washington, D.C. from December 16-19, ICAAC is a major scientific conference sponsored by the American Society for Microbiology bringing together more than 12,000 scientists and researchers from around the globe to address the impact of infectious diseases.
